Overview

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

Status:
Completed

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

This study will assess the safety, tolerability, and efficacy of SM04554 at concentrations of 0.15% and 0.25%. Improved knowledge of the changes in hair counts and immunohistochemical analysis associated with androgenetic alopecia (AGA) before and after treatment with SM04554 and compared to placebo may lead to a greater understanding of the underlying mechanisms of action of SM04554.

Phase:

Phase 2

Details

Lead Sponsor:

Biosplice Therapeutics, Inc.
Samumed LLC

Treatments:

Pharmaceutical Solutions